Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Sprycel dasatinib regulatory update

The companies said FDA approved an updated label for Sprycel dasatinib to include 3-year data in patients with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic phase chronic myelogenous leukemia (CML) from the Phase III DASISION trial and

Read the full 368 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers